ASP8374 + Cemiplimab in Recurrent Glioma

Clinical trial NCT04826393 · COMPLETED

Trial details

NCT number: NCT04826393
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Glioblastoma Recurrent Glioblastoma

Start date: 2022-03-09
Primary completion: 2022-10-31
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.